ONO-8539
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout ONO-8539
ONO-8539 is a phase 1 stage product being developed by Ono Pharmaceutical for Acid Reflux. The current trial status is completed. This product is registered under clinical trial identifier NCT01705275. Target conditions include Acid Reflux.
What happened to similar drugs?
4 of 12 similar drugs in Acid Reflux were approved
Approved (4) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01705275 | Phase 1 | Completed |
| NCT01707901 | Phase 1 | Completed |
Competing Products
20 competing products in Acid Reflux
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-3705 | Moderna | Phase 2 | 0 |
| "The MaP Study": Mapping the Patient Journey in MMA and PA | Moderna | Preclinical | 0 |
| mRNA-3704 | Moderna | Phase 2 | 0 |
| A Retrospective Study to Characterize Participants With Propionic Acidemia | Moderna | Preclinical | 0 |
| mRNA-3705 | Moderna | Phase 2 | 0 |
| mRNA-3927 | Moderna | Phase 2 | 0 |
| mRNA-3927 | Moderna | Phase 2 | 0 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 19 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 35 |
| Insulin (Aspart Insulin [Novolog], Regular Insulin) | Novo Nordisk | Pre-clinical | 26 |
| Pantoprazole | Pfizer | Approved | 43 |
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 29 |
| Olipudase alfa | Sanofi | Pre-clinical | 26 |
| insulin glargine+ glulisine + NPH + Regular insulin | Sanofi | Approved | 43 |
| Ataluren | Sanofi | Phase 2 | 27 |
| rhASM + rhASM + rhASM + rhASM + rhASM | Sanofi | Phase 1 | 21 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium + sodium bicarbonate | Bayer | Phase 3 | 37 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent) | Bayer | Phase 3 | 37 |
| Zegerid + Prilosec OTC™ Tablets | Bayer | Phase 3 | 37 |
| A3384 | Ipsen | Phase 2 | 32 |